{"id":"NCT00686374","sponsor":"AbbVie (prior sponsor, Abbott)","briefTitle":"Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806","officialTitle":"A Multi-center, Open-label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Efficacy and the Long-term Safety and Tolerability of Repeated Administration of Adalimumab in Pediatric Subjects With Crohn's Disease Who Have Demonstrated a Clinical Response in the M06-806 Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-05-01","primaryCompletion":"2017-04-04","completion":"2017-04-04","firstPosted":"2008-05-29","resultsPosted":"2018-04-20","lastUpdate":"2018-07-02"},"enrollment":100,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Crohn's Disease"],"interventions":[{"type":"BIOLOGICAL","name":"Adalimumab","otherNames":["ABT-D2E7","Humira"]}],"arms":[{"label":"Any adalimumab","type":"EXPERIMENTAL"}],"summary":"This was a multicenter, open-label study to evaluate the human monoclonal anti-TNF-Î± antibody adalimumab as an effective therapy for maintaining clinical response in pediatric participants with Crohn's disease (CD) and to gather long-term safety and tolerability data in this population. Participants were allowed to enroll in the study if they participated in and successfully completed Study M06-806 (NCT00409682) through Week 52.","primaryOutcome":{"measure":"Number of Participants Who Achieved Pediatric Crohn's Disease Activity Index (PCDAI) Clinical Remission Over Time","timeFrame":"Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408","effectByArm":[{"arm":"Any Adalimumab","deltaMin":67,"sd":null}],"pValues":[]},"eligibility":{"minAge":"7 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":15},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["28129288","30054164","29939254"],"seeAlso":["http://rxabbvie.com"]},"adverseEventsSummary":{"seriousAny":{"events":48,"n":100},"commonTop":["VIRAL UPPER RESPIRATORY TRACT INFECTION","HEADACHE","UPPER RESPIRATORY TRACT INFECTION","OROPHARYNGEAL PAIN","DIARRHOEA"]}}